Home Stock

Stock Research: BioLife Slutn

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

BioLife Slutn

NAQ:BLFS US09062W2044
74
  • Value
    9
  • Growth
    33
  • Safety
    Safety
    29
  • Combined
    34
  • Sentiment
    100
  • 360° View
    360° View
    74
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

BioLife Solutions, Inc. develops and supplies cell processing tools and services for the cell and gene therapy (CGT) market. The company operates in the cell and gene therapy market, offering solutions for cell preservation and processing. Its products include CryoStor freeze media, Sexton cell processing product line, CellSeal cryogenic vials, and ThawSTAR thawing devices. In the last fiscal year, the company had a market cap of $1,000 million, profits of $54 million, and revenue of $82 million with 159 employees.

more

ANALYSIS: With an Obermatt 360° View of 74 (better than 74% compared with alternatives), overall professional sentiment and financial characteristics for the stock BioLife Slutn are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for BioLife Slutn. The consolidated Sentiment Rank has a good rank of 100, which means that professional investors are more optimistic about the stock than for 100% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 9, which means that the share price of BioLife Slutn is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 33, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 33% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 29 which means that the company has a riskier financing structure than 71% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Sentiment
Country USA
Industry Life Sciences Tools & Services
Size Small
Website biolifesolutions.com
Index
NASDAQ
BioLife Slutn stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
9 20 44 63
Growth
33 91 27 71
Safety
Safety
29 20 56 56
Sentiment
100 82 33 17
360° View
360° View
74 71 81 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
87 84 61 23
Opinions Change
50 50 50 50
Pro Holdings
n/a 63 32 75
Market Pulse
95 40 36 16
Sentiment
100 82 33 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
9 20 44 63
Growth
33 91 27 71
Safety Safety
29 20 56 56
Combined
34 33 72 72
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
15 11 38 62
Price vs. Earnings (P/E)
3 58 58 6
Price vs. Book (P/B)
55 40 58 79
Dividend Yield
1 1 1 1
Value
9 20 44 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
86 4 10 71
Profit Growth
49 90 90 9
Capital Growth
13 95 9 91
Stock Returns
29 87 47 53
Growth
33 91 27 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
95 60 53 62
Refinancing
43 18 39 31
Liquidity
6 14 28 28
Safety Safety
29 20 56 56

Similar Stocks

Discover high‑ranked alternatives to BioLife Slutn and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

Only the professional market sentiment is positive. The stock is expensive, has low growth, and low financial safety. This is a weak investment proposition. Only a small, highly-speculative investment may be justified by investors who strongly believe the positive sentiment points to an positive future.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews